This article and associated images are based on a poster originally authored by Frances Hall and Brenda Finney and presented at ELRIG Drug Discovery 2026 in affiliation with Instem. This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment. The challenge in modern drug discovery is not generating data, but rather transforming these diverse experimental findings into actionable insights that improve predictions and support translational decision-making. As organizations adopt AI-driven approaches, the need for connected, high-quality, and analysis-ready data has never been greater. In this context, lab-in-the-loop strategies provide a mechanism for continuously learning from experimental outcomes, enabling better experiments, better models, and ultimately better development decisions. The translational learning circle Image Credit: Image courtesy of Frances Hall and Brenda Finney in partnership with ELRIG (UK) Ltd. Real-world use case The challenge: Toxicology data is often fragmented across studies, projects, and departments, making it difficult to quickly answer scientific questions or reuse prior knowledge. How Centrus helps: Centralizes preclinical and SEND data...

One Nucleus, The Society for Laboratory Automation and Screening (SLAS), and ELRIG today announced that they will be collaborating during the second London

London Bio-innovation Week Additional opportunities to meet the life science ecosystem around Genesis London Bio-innovation Week is a series of satellite events in London that are planned for the days leading into the...

This article and associated images are based on a poster originally authored by Rebecca Ram and presented at ELRIG Drug Discovery 2026 in affiliation with Lush Prize. This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment. The Lush Prize is a £250,000 award supporting initiatives in modern, innovative, and more human-relevant approaches to drive forward drug discovery and disease research and achieve an urgently needed transition away from animal testing. Prize categories There are five main prize categories: Science, Training, Public Awareness, Political Advocacy, and Young Researcher (early career scientists). There are additional Recognition Awards, including for Major Science Collaboration. Nominations are open to individuals or teams in any country. Winners of the Lush Prize 2026 Young Researcher Award. Image Credit: Image courtesy of Rebecca Ram, in partnership with ELRIG (UK) Ltd. Roadmaps Recent developments in roadmaps to phase out animal testing, both in the UK and worldwide, recognize the need for a new way forward in drug discovery and biomedical...

This article and associated images are based on a poster originally authored by Rebecca Ram and presented at ELRIG Drug Discovery 2026 in affiliation with

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, and The Protein Society, an international, not-for-profit, scholarly society, with the mission to provide forums for the advancement of research into protein structure, function, design and applications, today announced the keynote speakers for Protein Sciences in Drug Discovery 2026. Prof Dame Carol Robinson DBE FRS FMedSci FRSC, Director of the Kavli Institute for Nanoscience Discovery at the University of Oxford; Dr Andrew Doré, Head of Structural Biology at Isomorphic Labs; and Prof Paula Booth, Daniell Chair of Chemistry at King’s College London (KCL), will lead this year’s conference taking place at GSK Stevenage from 10–11 November 2026. The free-to attend event offers scientists from academia, pharma, biotech and CROs the opportunity to explore emerging developments in protein science and their application to modern drug discovery. The program will explore AI and machine learning in protein science; challenging targets and complexes; antibody and alternative biologic developability and quality control; and the production challenges associated with non-standard binding proteins. There will be valuable networking opportunities to exchange ideas, build new connections and explore potential collaborations, alongside meeting technology and service providers through the exhibition. Early Career Professionals will also be...